The cytochrome P450 inhibitor ketoconazole potentiates 5-hydroxytryptamine- induced contraction in rat aorta

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 606-613

  Ogden, Kevin K ^a   Falck, John R ^b   Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; ACETYLCHOLINE; AMITROLE; CATALASE; CLOTRIMAZOLE; CYTOCHROME P450; KETOCONAZOLE; N(G) NITROARGININE; PHENYLEPHRINE; POTASSIUM CHLORIDE; SEROTONIN; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; AORTA CONSTRICTION; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; ENDOTHELIUM; MALE; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AORTA, THORACIC; CATALASE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; ENZYME INHIBITORS; KETOCONAZOLE; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SUPEROXIDES; VASOCONSTRICTION;

EID: 35549005933     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.128454     Document Type: Article

References (28)

1. Brophy CM, Knoepp L, Xin J, and Pollock JS (2000) Functional expression of NOS1 in vascular smooth muscle. Am J Physiol 278:H991-H997.
2. 2 receptors mediating contraction in vascular smooth muscle. J Pharmacol Exp Ther 218:421-425.
3. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, and Morawietz H (2000) Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 24:713-717.
4. Emoto C, Murase S, Sawada Y, Jones BC, and Iwasaki K (2003) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18:287-295.
5. 2A receptor signal transduction. J Pharmacol Exp Ther 284:346-355.
6. Fradette C, Yamaguchi N, and du Souich P (2004) 5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted in nitric oxide. Br J Pharm 141:407-414.
7. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, and Campbell WB (2002) 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90:1028-1036.
8. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RR (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148.
9. Griendling KK, Sorescu D, and Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494-501.
10. Harrington LS, Falck JR, and Mitchell JA (2004) Not so EEZE: the 'EDHF' antagonist 14,15 epoxyeicosa-5(Z)-enoic acid has vasodilator properties in mesenteric arteries. Eur J Pharmacol 506:165-168.
11. He H, Podymow T, Zimpelmann J, and Burns KD (2003) NO inhibits Na+-K+-2Cl-cotransport via a cytochrome P-450 dependent pathway in renal epithelial cells (MMDD1). Am J Physiol 284:F1235-F1244.
12. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, and Maurel P (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 6:752-758.
13. McGregor DD and Smirk FH (1970) Vascular responses to 5-hydroxytryptamine in genetic andrenal hypertensive rats. Am J Physiol 219:687-690.
14. Meredith CG, Maldonado AL, and Speeg KV Jr (1985) The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab Dispos 13:156-162.
15. Nemecek GM, Coughlin SR, Handley DA, and Moskowitz MA (1986) Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A 83:674-678.
16. Ni W and Watts SW (2006) 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 33:575-583.
17. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
18. Polsky-Fisher SL, Cao H, Lu P, and Gibson CR (2006) Effect of cytochrome P450 chemical inhibitors and monoclonal antibodies on human liver microsomal esterase activity. Drug Metab Dispos 34:1361-1366.
19. Randriamboavonjy V, Kiss L, Falck JR, Busse R, and Fleming I (2005) The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation. Cardiovasc Res 65:487-494.
20. Rao GN and Berk BC (1992) Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70:593-599.
21. Roman RJ (2002) P450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
22. 2B): where structure meets function. Pharmacol Ther 79: 231-257.
23. Saadeddin A, Torres-Molina F, Carcel-Trullols J, Araico A, and Peris J (2004) Effect of cytochrome P450 inhibitors (diethyl cithiocarbamate, ketoconazole and grapefruit juice) on the pharmacokinetics of all-trans-retinoic acid. Farmaco 59:696-702.
24. Sheets JJ and Mason JI (1984) Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab Dispos 12:603-606.
25. Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, et al. (2004) Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105-112.
26. Touyz RM and Schiffrin EL (2004) Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122:339-352.
27. Turla MB and Webb RC (1989) Vascular responsiveness to 5-hydroxytryptamine in experimental hypertension, in The Peripheral Actions of 5-Hydroxytryptamine (Fozard JR ed) pp 327-353, Oxford University Press, Oxford, UK.
28. Watts SW (1998) The development of enhanced arterial serotonergic hyperresponsiveness in mineralocorticoid hypertension. J Hypertension 16:811-822.